Galderma’s Restylane Fillers Receive FDA Approval

December 28, 2016

Galderma, a global medical solutions company focusing on skin health, received U.S. Food and Drug Administration (FDA) approval of two new products for the treatment of nasolabial folds, commonly known as laugh lines. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkles and folds and Restylane Defyne for the treatment of moderate to severe, deep facial wrinkles and folds. These scientifically advanced gels are manufactured with XpresHAn Technology, which allows for a range of flexibility and support for varied patient needs, and effective treatment for up to 12 months. “Even with current approved options, many of my patients are still looking for different solutions to treat their laugh lines,” says Steven Fagien, M.D., Boca Raton-based oculoplastic surgeon and Restylane Refyne clinical investigator. “These new products are flexible and are designed to meet different patient needs. I am excited to offer these next-generation hyaluronic acid (HA) dermal fillers in my practice.”
Read more at American Spa Magazine >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Dermalogica Launches FDA-Cleared PRO Pen Microneedling System
    • Regenerative Aesthetics Is Evolving. Are You Keeping Up?
    • Influx Marketing Introduces Growthstack, a New All-In-One Growth Platform Built for Med Spas
    • AbbVie Receives FDA Complete Response Letter for TrenibotulinumtoxinE
    • ByrdAdatto Named to D Magazine’s 2026 Best Lawyers in Dallas List